EP1753437B1 - Solutions a base de bicarbonate pour dialyse peritoneale - Google Patents
Solutions a base de bicarbonate pour dialyse peritoneale Download PDFInfo
- Publication number
- EP1753437B1 EP1753437B1 EP05754137.7A EP05754137A EP1753437B1 EP 1753437 B1 EP1753437 B1 EP 1753437B1 EP 05754137 A EP05754137 A EP 05754137A EP 1753437 B1 EP1753437 B1 EP 1753437B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- solution
- dialysis
- bicarbonate
- concentrate
- dialysis solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000385 dialysis solution Substances 0.000 title claims description 66
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 title claims description 45
- 239000000243 solution Substances 0.000 claims description 119
- 239000012141 concentrate Substances 0.000 claims description 64
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 34
- 230000002378 acidificating effect Effects 0.000 claims description 33
- 239000002357 osmotic agent Substances 0.000 claims description 30
- 239000008103 glucose Substances 0.000 claims description 29
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 22
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- 239000000872 buffer Substances 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 17
- 239000011259 mixed solution Substances 0.000 claims description 15
- 229920002177 Icodextrin Polymers 0.000 claims description 11
- 239000004310 lactic acid Substances 0.000 claims description 11
- 235000014655 lactic acid Nutrition 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 10
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 10
- 229940016836 icodextrin Drugs 0.000 claims description 10
- 229940076788 pyruvate Drugs 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 230000004102 tricarboxylic acid cycle Effects 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 230000004888 barrier function Effects 0.000 claims description 3
- 229940107700 pyruvic acid Drugs 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 description 65
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000001954 sterilising effect Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000001631 haemodialysis Methods 0.000 description 12
- 230000000322 hemodialysis Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 238000004659 sterilization and disinfection Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 239000002699 waste material Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 239000003053 toxin Substances 0.000 description 9
- 231100000765 toxin Toxicity 0.000 description 9
- 108700012359 toxins Proteins 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000003200 peritoneal cavity Anatomy 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 208000001647 Renal Insufficiency Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- -1 for example Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000002615 hemofiltration Methods 0.000 description 5
- 201000006370 kidney failure Diseases 0.000 description 5
- 239000003792 electrolyte Chemical class 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 229930182843 D-Lactic acid Natural products 0.000 description 3
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 239000004368 Modified starch Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011340 continuous therapy Methods 0.000 description 2
- 238000011975 continuous veno-venous hemodiafiltration Methods 0.000 description 2
- 238000011974 continuous veno-venous hemodialysis Methods 0.000 description 2
- 238000011973 continuous veno-venous hemofiltration Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000012959 renal replacement therapy Methods 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical class [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
Definitions
- the present invention relates generally to solutions used for dialysis therapy.
- a person's renal system can fail.
- renal failure of any cause there are several physiological derangements. The balance of water, minerals and the excretion of daily metabolic load are no longer possible in renal failure.
- toxic end products of nitrogen metabolism e.g., urea, creatinine, uric acid, and others
- Kidney failure and reduced kidney function have been treated with dialysis. Dialysis removes waste, toxins and excess water from the body that would otherwise have been removed by normal functioning kidneys. Dialysis treatment for replacement of kidney functions is critical to many people because the treatment is life saving. One who has failed kidneys could not continue to live without replacing at least the filtration functions of the kidneys.
- Hemodialysis, hemofiltration and peritoneal dialysis are three types of dialysis therapies generally used to treat loss of kidney function.
- Hemodialysis treatment removes waste, toxins and excess water directly from the patient's blood.
- the patient is connected to a hemodialysis machine and the patient's blood is pumped through the machine.
- needles or catheters can be inserted into the patient's veins and arteries to connect the blood flow to and from the hemodialysis machine.
- the dialyzer removes the waste, toxins and excess water from the patient's blood and returns the blood to infuse back into the patient.
- a large amount of dialysate for example about 90-120 liters, is used by most hemodialysis machines to dialyze the blood during a single hemodialysis therapy. The spent dialysate is then discarded. Hemodialysis treatment lasts several hours and is generally performed in a treatment center about three times per week.
- Hemofiltration is a convection-based blood cleansing technique.
- Blood access can be venovenous or arteriovenous.
- a transmembrane pressure gradient between the blood compartment and the ultrafiltrate compartment causes plasma water to be filtered across the highly permeable membrane.
- As the water crosses the membrane it convects small and large molecules across the membrane and thus cleanses the blood.
- An excessive amount of plasma water is eliminated by filtration. Therefore, in order to keep the body water balanced, fluid must be substituted continuously by a balanced electrolyte solution (replacement or substitution fluid) infused intravenously.
- This substitution fluid can be infused either into the arterial blood line leading to the hemofilter (predilution) or into the venous blood line leaving the hemofilter.
- Peritoneal dialysis utilizes a sterile dialysis solution or "dialysate", which is infused into a patient's peritoneal cavity and into contact with the patient's peritoneal membrane. Waste, toxins and excess water pass from the patient's bloodstream through the peritoneal membrane and into the dialysate. The transfer of waste, toxins, and excess water from the bloodstream into the dialysate occurs due to diffusion and osmosis during a dwell period as an osmotic agent in the dialysate creates an osmotic gradient across the membrane. The spent dialysate is later drained from the patient's peritoneal cavity to remove the waste, toxins and excess water from the patient.
- CAPD continuous ambulatory peritoneal dialysis
- automated peritoneal dialysis CAPD is a manual dialysis treatment, in which the patient connects the catheter to a bag of fresh dialysate and manually infuses fresh dialysate through the catheter or other suitable access device and into the patient's peritoneal cavity. The patient disconnects the catheter from the fresh dialysate bag and allows the dialysate to dwell within the cavity to transfer waste, toxins and excess water from the patient's bloodstream to the dialysate solution. After a dwell period, the patient drains the spent dialysate and then repeats the manual dialysis procedure.
- Tubing sets with "Y" connectors for the solution and drain bags are available that can reduce the number of connections the patient must make.
- the tubing sets can include pre-attached bags including, for example, an empty bag and a bag filled with dialysate.
- each treatment cycle which includes a drain, fill and dwell, takes about four hours.
- Automated peritoneal dialysis is similar to continuous ambulatory peritoneal dialysis in that the dialysis treatment includes a drain, fill, and dwell cycle. However, a dialysis machine automatically performs three or more cycles of peritoneal dialysis treatment, typically overnight while the patient sleeps.
- an automated dialysis machine fluidly connects to an implanted catheter.
- the automated dialysis machine also fluidly connects to a source or bag of fresh dialysate and to a fluid drain.
- the dialysis machine pumps spent dialysate from the peritoneal cavity, through the catheter, to the drain.
- the dialysis machine then pumps fresh dialysate from the dialysate source, through the catheter, and into the patient's peritoneal cavity.
- the automated machine allows the dialysate to dwell within the cavity so that the transfer of waste, toxins and excess water from the patient's bloodstream to the dialysate solution can take place.
- a computer controls the automated dialysis machine so that the dialysis treatment occurs automatically when the patient is connected to the dialysis machine, for example, when the patient sleeps. That is, the dialysis system automatically and sequentially pumps fluid into the peritoneal cavity, allows for dwell, pumps fluid out of the peritoneal cavity, and repeats the procedure.
- peritoneal dialysis solutions contain glucose as an osmotic agent to maintain the osmotic pressure of the solution higher than the physiological osmotic pressure (i.e. higher than about 285 mOsmol/kg).
- glucose is a preferred osmotic agent because it provides rapid ultrafiltration rates.
- Other types of osmotic agents are generally known and used in addition to or as a substitute for glucose.
- glucose polymers such as icodextrins, maltodextrins and the like.
- these compounds are also known to be sensitive to low and high pH, especially during sterilization and long-term storage.
- US-6,689,393 discloses a three-part peritoneal dialysis solution.
- the first solution contains calcium ions, electrolyte salts and optionally glucose and is acidified to a pH of less than 4.0.
- the second solution contains glucose and also has a pH of less than 4.0.
- the third solution contains a buffer and preferably has a pH of from 8.5 to 9.0. The three solutions are mixed to give a solution having a pH of from 6.8 to 7.4.
- US-2002/0012707 discloses a bicarbonate-based peritoneal dialysis solution in two parts.
- the first part is an alkaline bicarbonate concentrate having a pH of from 8.6 to 10.0.
- the second part is an acidic concentrate having a pH of from 1.0 to 3.0.
- the two concentrates are mixed to give a solution having a pH with an acceptable physiological range.
- WO 01/89478 discloses peritoneal dialysis solutions in multiple compartment containers.
- the osmotic agent is stabilized with a bisulphite buffer, preferably at pH:3.2.
- the present invention relates generally to dialysis solutions and methods of making same and systems including same. More specifically, the present invention relates to peritoneal dialysis solutions that include multiple solution parts to enhance the stability, biocompatibility, and overall effectiveness of ready-to-use dialysis solutions made from an admixture of same.
- the present invention provides a multi-chamber bag configuration that allows the storage of chemically incompatible components, such as pH-sensitive ingredients, in a separate compartment.
- the pH-sensitive ingredients include glucose polymers.
- glucose polymers can be used in addition to or as a substitute for dextrose as an osmotic agent within dialysis solutions.
- Applicants have recognized that the stability of the dialysis solution based with glucose polymers can be enhanced by preparing, storing and sterilizing the pH-sensitive ingredient within a separate solution part at an effective pH level for such purpose.
- the overall effectiveness of the ready-to-use dialysis solution can be enhanced.
- the pH-sensitive component solution part is buffered (e.g., with lactate and/or other suitable buffer), while the other two solution component parts are formulated as to obtain a bicarbonate-containing solution at physiological pH upon mixing of the respective concentrates. This can further enhance the stability of the pH-sensitive solution part.
- the two additional solution component parts contain an acidic concentrate that includes lactic acid, for example, and an alkaline concentrate containing a bicarbonate buffer, respectively, wherein the bicarbonate ingredient is stable without gas-barrier overpouch. The mixture of the two additional solution component parts can then be added to the pH-sensitive solution part to form the ready-to-use dialysis solution.
- the present invention provides a bicarbonate containing dialysis solution.
- the bicarbonate containing dialysis solution includes a first part housed in a first container, the first part including an alkaline bicarbonate concentrate with a pH ranging from about 8.6 to about 10.0; a second part housed in a second container, the second part including an acidic concentrate with a pH of about 4.0 or less; and a third part housed in a third container, the third part including a buffer, a pH-sensitive ingredient including a glucose polymer and having a pH of from 4.0 to 8.6 wherein the pH-sensitive ingredient does not remain stable when sterilized in any one of the first container and the second container, and wherein the pH of the second part and the third part are effective to obtain a mixed solution with a physiologically acceptable pH, such as ranging from about 6.5 to about 7.6, when the first part, the second part and the third part are mixed together.
- a physiologically acceptable pH such as ranging from about 6.5 to about 7.6, when the first part, the
- the first container is a first chamber of a multi-chamber container
- the second container is a second chamber of a multi-chamber container
- the third container is a third chamber of a multi-chamber container such that the first part, the second part and the third part can be mixed within the multi-chamber container to form the mixed solution.
- the mixed solution comprises bicarbonate 0.5 mM to 45 mM; and calcium 0.2 mM to 2.0 mM.
- the mixed solution comprises bicarbonate 0.5 mM to 45 mM; calcium 0.2 mM to 2.0 mM; sodium 100 mM to 150 mM; magnesium 0 mM to 1.5 mM; potassium 0 mM to 4.5 mM; chloride 70 mM to 120 mM; lactate 0 mM to 60 mM; acetate 0 mM to 60 mM; citrate 0 mM to 60 mM; and pyruvate 0 mM to 60 mM.
- the bicarbonate containing dialysis solution further comprises one or more osmotic agents selected from glucose, modified starch, hydroxyethyl starch, polyols, amino acids, peptides, glycerol and the like.
- the first container, the second container and the third container are constructed of a gas permeable material.
- a three-part bicarbonate solution for peritoneal dialysis includes a first part stored in a first container and including an alkaline bicarbonate concentrate with a pH ranging from about 8.6 to about 10.0; a second part stored in a second container and including an acidic concentrate with a pH less than about 4.0; and a third part stored in a third container and including a concentrate with a pH ranging from about 4.0 to about 8.6 wherein the concentrate includes a pH-sensitive osmotic agent comprising a glucose polymer and a buffer, and wherein the first part, the second part and the third part are admixed to form a mixed solution with a pH ranging from about 6.5 to about 7.6 that comprises bicarbonate 0.5 mM to 45 mM; calcium 0.2 mM to 2.0 mM; sodium 100 mM to 150 mM; magnesium 0 mM to 1.5 mM; potassium 0 mM to 4.5 mM; chloride 70 m
- the first container is a first chamber of a multi-chamber container
- the second container is a second chamber of a multi-chamber container
- the third container is a third chamber of a multi-chamber container such that the first part, the second part and the third part can be mixed within the multi-chamber container to form the mixed solution.
- the pH-sensitive osmotic agent includes a glucose polymer.
- the three-part bicarbonate dialysis solution further comprises an osmotic agent that includes a glucose, a modified starch, one or more amino acids, one or more peptides, a glycerol, the like and combinations thereof.
- an osmotic agent that includes a glucose, a modified starch, one or more amino acids, one or more peptides, a glycerol, the like and combinations thereof.
- the first container, the second container and the third container are constructed of a gas permeable material.
- the third part is buffered with a buffer agent that includes lactate, pyruvate, acetate, citrate, an intermediate of the KREBS cycle, the like and combinations thereof.
- a buffer agent that includes lactate, pyruvate, acetate, citrate, an intermediate of the KREBS cycle, the like and combinations thereof.
- the acidic concentrate includes lactic acid/lactate, pyruvic acid/pyruvate, acetic acid/acetate, citiric acid/citrate an intermediate of the KREBS cycle, hydrochloric acid, and combinations thereof.
- a method of preparing a dialysis solution includes preparing a first part housed in a first container, a second part housed in a second container and a third part housed in a third container wherein the first part includes an alkaline bicarbonate concentrate with a pH ranging from about 8.6 to about 10.0, wherein the second part includes an acidic concentrate with a pH ranging from about 4.0 or less, and wherein the third part includes a buffer and a pH-sensitive osmotic agent comprising a glucose polymer and has a pH of from 4.0 to 8.6; mixing the first part and the second part to form a solution mixture; and mixing the third part with the solution mixture to form a ready-to-use dialysis solution that has a pH ranging from about 6.5 to about 7.6.
- the first part, the second part, and the third part are sterilized prior to forming the ready-to-use dialysis solution.
- the pH-sensitive osmotic agent is separately sterilized prior to mixing with the first part and the second part.
- the buffer is added to the third part to promote stabilization of the pH-sensitive osmotic agent.
- the buffer includes lactate, pyruvate, acetate, citrate, an intermediate of the KREBS cycle, the like and combinations thereof.
- the ready-to-use dialysis solution comprises bicarbonate 0.5 mM to 45 mM; calcium 0.2 mM to 2.0 mM; sodium 100 mM to 150 mM; magnesium 0 mM to 1.5 mM; potassium 0 mM to 4.5 mM; chloride 70 mM to 120 mM; lactate 0 mM to 60 mM; acetate 0 mM to 60 mM; citrate 0 mM to 60 mM; and pyruvate 0 mM to 60 mM.
- the ready-to-use dialysis solution further comprises an osmotic agent that includes a glucose, a modified starch, one or more amino acids, one or more peptides, a glycerol, the like and combinations thereof.
- an osmotic agent that includes a glucose, a modified starch, one or more amino acids, one or more peptides, a glycerol, the like and combinations thereof.
- a method of providing dialysis to a patient includes preparing a dialysis solution wherein the dialysis solution includes a first part, a second part and a third part that are admixed to form the dialysis solution.
- the first part includes an alkaline concentrate including bicarbonate and having a pH from about 8.6 to about 10.0; the second part includes an acidic concentrate with a pH less than about 4.0; and the third part includes an osmotic agent including a glucose polymer and has a pH ranging from about 4.0 to about 8.6 and further includes a buffer to promote stabilization of the osmotic agent.
- the method further includes using the dialysis solution during dialysis.
- the ready-to-use peritoneal dialysis solution is used during peritoneal dialysis, such as continuous ambulatory peritoneal dialysis, automated peritoneal dialysis and the like.
- the present invention provides a system for providing dialysis.
- the system includes a first part housed in a first container, wherein the first part includes an alkaline bicarbonate concentrate with a pH ranging from about 8.6 to about 10.0; a second part housed in a second container, wherein the second part includes an acidic concentrate with a pH less than about 4.0; and a third part housed in a third container, wherein the third part includes a buffer and a pH-sensitive osmotic agent including a glucose polymer and having a pH ranging from about 4.0 to about 8.6.
- the pH-sensitive osmotic agent does not remain stable when sterilized in any one of the first container and the second container, wherein a pH of the second part and the third part are effective to obtain, when the first part, the second part and the third part are mixed together, a mixed solution with a physiologically acceptable pH, ranging from about 6.5 to about 7.6.
- the system at least includes a tubing set that is adaptedly coupled to the first, second and third parts thereby allowing use of same during dialysis.
- the present invention provides a three-part bicarbonate solution for peritoneal dialysis.
- the solution includes a first part stored in a first container and including an alkaline bicarbonate concentrate with a pH ranging from about 8.6 to about 10.0; a second part stored in a second container and including an acidic concentrate with a pH less than about 4.0; and a third part stored in a third container and including a concentrate with a pH ranging from about 4.0 to about 5.5 wherein the concentrate includes a pH-sensitive osmotic agent including a glucose polymer and a buffer to further promote stabilization of the pH-sensitive osmotic agent, and wherein the first part, the second part and the third part are capable of being admitted to form a mixed solution with a pH ranging from about 6.5 to about 7.6.
- the third part includes about 15 mM or less of the buffer, such as about 10 mM or less.
- An advantage of the present invention is to provide improved dialysis solutions.
- Another advantage of the present invention is to provide dialysis solutions with improved biocompatibility characteristics.
- Yet another advantage of the present invention is to provide dialysis solutions with enhanced stability, such as during sterilization, storage and the like.
- Still yet another advantage of the present invention is to provide improved dialysis solutions that include separately formulated and sterilized solution parts to promote the stabilization of a pH-sensitive component in one or more of the solution parts.
- a further advantage of the present invention is to provide a lactate-buffered dialysis solution.
- a still further advantage of the present invention is to provide improved methods of making dialysis solutions.
- the present invention generally relates to dialysis solutions and methods of making same and systems including same. More specifically, the present invention relates to peritoneal dialysis solutions that include at least three solution parts. The solution parts are separately formulated, sterilized and stored prior to mixing to form a ready-to-use solution. This can enhance the stability, biocompatibility, and overall effectiveness of ready-to-use solutions.
- the present invention relates to bicarbonate-based dialysis solutions that are formulated from at least three separate solution parts, such as an alkaline bicarbonate concentrate in which the bicarbonate ingredient is stable without a gas barrier overpouch, an acidic concentrate containing lactic acid, for example, and a concentrate containing an osmotic agent, and/or any other solution ingredient, such as an additive, which does not remain stable when sterilized/stored in the remaining other solution compartments.
- the solution parts are designed to provide a final solution with an acceptable pH in the physiological range upon mixing.
- the dialysis solutions of the present invention can be used in a variety of suitable applications.
- the dialysis solutions are used during peritoneal dialysis, such as during continuous ambulatory peritoneal dialysis, automated peritoneal dialysis, and the like.
- the present invention can be used in a variety of different and suitable dialysis therapies to treat kidney failure.
- Dialysis therapy as the term or like terms are used throughout the text is meant to include and encompass any and all suitable forms of therapies that utilize the patient's blood to remove waste, toxins and excess water from the patient.
- Such therapies such as hemodialysis, hemofiltration and hemodiafiltration, include both intermittent therapies and continuous therapies used for continuous renal replacement therapy (CRRT).
- CRRT continuous renal replacement therapy
- the continuous therapies include, for example, slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), continuous venovenous hemodiafiltration (CVVHDF), continuous arteriovenous hemofiltration (CAVH), continuous arteriovenous hemodialysis (CAVHD), continuous arteriovenous hemodiafiltration (CAVHDF), continuous ultrafiltration periodic intermittent hemodialysis or the like.
- the dialysis solutions are used during peritoneal dialysis, such as automated peritoneal dialysis, continuous ambulatory peritoneal dialysis, continuous flow peritoneal dialysis and the like.
- the present invention in an embodiment, can be utilized in methods providing a dialysis therapy for patients having chronic kidney failure or disease, it should be appreciated that the present invention can be used for acute dialysis needs, for example, in an emergency room setting.
- the intermittent forms of therapy i.e., hemofiltration, hemodialysis, peritoneal dialysis and hemodiafiltration
- the three-part dialysis solutions of the present invention can include any suitable number, type and amount of solution components. Applicants have found that the stability of the pH-sensitive osmotic agent solution part can be enhanced by preparing, sterilizing and storing this solution part at an effective pH range and separated from the remaining other solution parts. Prior to use, the pH-sensitive solution part can be admixed with the remaining other solution parts to form the ready-to-use solution.
- the term "pH-sensitive component” or other like terms means any suitable type of solution component that remains stable at an intermediate pH level as compared to the pH of the acidic concentrate, the bicarbonate concentrate and other like solution parts associated with a multi-part dialysis solution.
- the pH-sensitive component can remain stable at a pH ranging from about 3.0 to about 8.6 during preparation, sterilization, storage and otherwise condition until use thereof in an embodiment.
- the pH-sensitive component includes an osmotic agent comprising a glucose polymer that remains stable at the pH range as discussed above.
- the pH can range from about 4.0 to about 5.5 according to an embodiment.
- the pH-sensitive osmotic agent includes a glucose polymer.
- glucose polymers such as icodextrin
- icodextrin can be used in addition to or in place of dextrose in peritoneal dialysis solutions.
- icodextrin is a polymer of glucose derived from the hydrolysis of corn starch. It has a molecular weight of 12-20,000 Daltons. The majority of glucose molecules in icodextrin are linearly linked with ⁇ (1-4) glucosidic bonds (>90%) while a small fraction ( ⁇ 10%) is linked by ⁇ (1-6) bonds.
- the pH-sensitive component solution part can include any number of suitable other types of components.
- the pH-sensitive component part also includes a buffer, such as an organic acid including, for example, lactate, pyruvate, acetate, citrate, an intermediate of the KREBS cycle, the like and combinations thereof.
- the buffer addition can further enhance the stability of the pH-sensitive solution component part.
- the additional solution components of the dialysis solutions of the present invention at least include a bicarbonate-based concentrate and an acidic concentrate.
- the bicarbonate-based concentrate can include any suitable type and amount of solution components.
- the bicarbonate concentrate is an alkaline solution such that the bicarbonate can remain stable without the use a gas barrier overpouch or the like.
- the bicarbonate concentrate has a pH that ranges from about 8.6 to about 10.0, preferably about 9.0.
- the pH of the bicarbonate solution part can be adjusted with any suitable type of component, such as sodium hydroxide and/or the like.
- Illustrative examples of the bicarbonate solution part of the present invention can be found in U.S. Patent No.
- the acidic concentrate solution part can include any suitable type, amount and number of components.
- the acidic concentrate includes one or more physiological acceptable acids, such as lactic acid, pyruvic acid, acetic acid, citric acid, hydrochloric acid and the like.
- the acidic concentrate has a pH that can be lower than the remaining other solution parts.
- the pH is about 4.0 or less, such as about 3.0 or less, about 2.0 or less, about 1.0 or less, and any other suitable acidic pH.
- a predetermined amount of acid (H+ ions) needs to be present in the solutions parts excluding the bicarbonate solution part for stability purposes. This can be in the form of hydrochloric acid, lactic acid, or any other physiologically acceptable acid as discussed above.
- lactic acid allows formulation of the acidic concentrate at a less acidic pH than when using concentrated hydrochloric acid.
- an organic acid such as lactic acid
- another suitable acid such as a suitable inorganic acid including hydrochloric acid, another suitable organic acid and the like in the acidic concentrate solution can make the solution part more physiologically tolerable according to an embodiment.
- the dialysis solutions of the present invention can include other solution components in addition to those components described above.
- any one or combination of suitable solution parts can include one or more electrolytes.
- electrolytes include calcium, magnesium, sodium, chloride and/or the like.
- the electrolytes are added to the pH-sensitive solution part and the acidic concentrate solution part.
- sodium and/or chloride can be added to any one or a combination of the three solution parts including the pH-sensitive solution part, the bicarbonate-based solution part and the acidic concentrate solution part.
- the difference between the three tested configurations is due from the amount of lactate present in the intermediate pH (e.g., icodextrin-containing) compartment as follows and further shown below: 0 mM (solution 1), 10 mM (solution 2), and 15 mM (solution 3).
- the ratio of the alkaline concentrate, the acidic concentrate, and the intermediate pH concentrate was chosen to be 1:1:2.
- the bicarbonate and sodium hydroxide concentrations in the alkaline bicarbonate containing concentrate were predetermined and required 26.7 mM H+ in the acidic concentrate for neutralization. Because the lactate concentration in the mixed solution was also predetermined at 10 mM, the lactate concentration in the intermediate pH compartment dictated the maximal amount of lactic acid and lactate that could be added to the acidic compartment.
- the pH results obtained on non-sterilized and sterilized solutions demonstrated that the addition of small amounts of lactate to the intermediate pH (e.g., icodextrin-containing) compartment prevents a pH-drop during sterilization.
- the results also show that the pH of the three acidic concentrates varies in function of the composition of lactic acid, lactate and hydrochloric acid.
- the mixed solutions displayed both a physiological pH and a physiological pCO 2 as further illustrated above.
- the solution parts of the dialysis solutions of the present invention can be housed or contained in any suitable manner such that the dialysis solutions can be effectively prepared, sterilized, stored and used.
- the present invention includes a multi-part dialysis solution in which three or more solution parts are formulated, stored and sterilized separately, and then mixed just prior to use.
- a variety of containers can be used to house the various parts of the dialysis solution, such as separate containers (e.g., flasks or bags) that are connected by a suitable fluid communication mechanism.
- a multi-chamber container or bag can be used to house the separate solution parts including the pH-sensitive solution part, the bicarbonate-based solution part and the acidic concentrate solution part.
- the separate components are mixed within the multi-chamber bag prior to use, such as during continuous ambulatory peritoneal dialysis.
- FIG. 1 illustrates a suitable container for storing, formulating, mixing and administering a dialysis solution, such as during continuous ambulatory peritoneal dialysis, according to an embodiment of the present invention.
- the multi-chamber bag 10 has a first chamber 12, a second chamber 14, and a third chamber 16.
- the interior of the container is divided by a peelable seal 18 into the three chambers.
- the peelable seal allows for the mixing of the solution components that are contained within each chamber as described in greater detail below.
- any suitable device on its own or in combination with the peelable seal, can be used to allow mixing of the solution components.
- the bag 10 can be divided into separate chambers by a heat seal material where connectors are provided to allow mixing of the solution components between the chambers.
- the connector includes a frangible connector, any suitable other type of connector and combinations thereof. It should be further appreciated that the volume ratio of the chambers can be arranged and configured in any suitable manner. As further shown in Fig. 1 , the bag 10 includes a port 20 attached to each chamber through which a respective solution component or mixture thereof can flow.
- the multi-chamber bag 10 contains the three solution parts as previously discussed.
- the alkaline bicarbonate solution part 22 is contained within the first chamber 12; the acidic concentrate solution part 24 is contained within the second chamber 14; and the pH-sensitive or intermediate pH solution part 26 is contained within the third chamber 16.
- the bicarbonate-based solution part 22 is then mixed with the acidic concentrate solution part 24. This mixture is further mixed with the pH-sensitive solution part to form a ready-to-use dialysis solution within the multi-chambered bag 10.
- the ready-to-use solution can then be administered to a patient through a respective port in any suitable manner.
- the multi-chamber bag can be modified and configured in any suitable way to separately contain the solution parts and further allow for admixing of same. Further, the solution parts can be admixed in any suitable sequence.
- An example of a multi-chamber bag can be found in U.S. Patent No. 4,465,488 , entitled COLLAPSIBLE MULTI-CHAMBER MEDICAL FLUID CONTAINER, issued on August 14, 1984; and U.S. Patent No. 4,396,383 , entitled MULTIPLE CHAMBER SOLUTION CONTAINER INCLUDING POSITIVE TEST FOR HOMOGENOUS MIXTURE, issued on August 2, 1983.
- the multi-chamber bag can be made of a gas permeable material, such as polypropylene, polyvinyl chloride and the like.
- the solution parts can be prepared, sterilized and stored in separate containers and then mixed via an admix device prior to use, such as applied during automated peritoneal dialysis.
- the bicarbonate concentrate 28, the acidic concentrate 30, and the pH-sensitive or intermediate pH concentrate 32 are stored in respective separate containers 34, 36 and 38 or bags which are fluidly connected to an admix device 40 suitable for use during automated peritoneal dialysis, an example of which includes ADMIX HOMECHOICE by BAXTER INTERNATIONAL, INC..
- other solution bags such as solution bag 42, can also be used during dialysis therapy as generally known.
- an effective amount of the solution concentrates are drawn from each respective container and into a heater bag 44 where the solution concentrates can be mixed and heated prior to infusion into a patient 46 during dialysis therapy.
- a drain line 48 is coupled to the admix device 40 from which waste fluids can be removed from the patient during therapy.
- the present invention provides systems for providing dialysis.
- the systems include multi-part solution components, such as the first, second and third solutions parts, that can be admixed to form a ready-to-use solution for dialysis as previously discussed.
- the systems at least include a tubing set or the like adaptedly coupled to the various solution parts thereby allowing use of same during dialysis, such as continuous peritoneal dialysis and automated peritoneal dialysis as discussed above.
- the tubing set can be configured in any suitable manner and be made of any suitable material or materials. As shown in Fig.
- the ready-to-use solution that is prepared in the multi-chamber bag 10 can be sent to a patient via a tubing set 50 during continuous ambulatory peritoneal dialysis.
- the solution parts are sent via tubing to a mixing device and subsequently to the patent during automated peritoneal dialysis.
- glucose can be added to the acidic concentrate and, optionally, amino acids can be added to the alkaline concentrate.
- Glucose can then be sterilized at an effectively low pH, thus preventing the formation of glucose degradation products.
- the amino acids can be sterilized separately in the alkaline solution part.
- the pH sensitive osmotic agent can be sterilized in its own compartment at an appropriately buffered pH.
- the pH sensitive component e.g., the pH-sensitive osmotic agent
- the multi-chamber bag can be configured in any suitable manner.
- the volume ratios of the different and separate chambers can vary depending on the application thereof.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (10)
- Solution de dialyse comprenant :un premier composant comportant un concentré de bicarbonate présentant un pH compris entre 8,6 et 10,0 ;un deuxième composant contenu séparément par rapport au premier composant, le deuxième composant comportant un concentré acide présentant un pH inférieur ou égal à 4,0 ; etun troisième composant contenu séparément par rapport au premier composant et au deuxième composant, le troisième composant comportant un tampon et un agent osmotique comprenant un polymère de glucose, le troisième composant présentant un pH compris entre 4,0 et 8,6.
- Solution de dialyse selon la revendication 1, dans laquelle le concentré de bicarbonate ne nécessite pas de sur-poche de barrière au gaz, avant utilisation.
- Solution de dialyse selon la revendication 1 ou 2, dans laquelle la solution après mélange comprend :de 0,5 mM à 45 mM de bicarbonate ; etde 0,2 mM à 2,0 mM de calcium.
- Solution de dialyse selon la revendication 3, dans laquelle la solution après mélange comprend :de 0,5 mM à 45 mM de bicarbonate ;de 0,2 mM à 2,0 mM de calcium ;de 100 mM à 150 mM de sodium ;de 0 mM à 1,5 mM de magnésium ;de 0 mM à 4,5 mM de potassium ;de 70 mM à 120 mM de chlorure ;de 0 mM à 60 mM de lactate ;de 0 mM à 60 mM d'acétate ;de 0 mM à 60 mM de citrate ; etde 0 mM à 60 mM de pyruvate.
- Solution de dialyse selon l'une quelconque des revendications 1 à 4, dans laquelle le tampon est sélectionné à partir du groupe constitué par du lactate, du pyruvate, de l'acétate, du citrate, un produit intermédiaire du cycle de Krebs, et des mélanges de ceux-ci.
- Solution de dialyse selon l'une quelconque des revendications précédentes, dans laquelle le troisième composant comporte 15 mM ou moins du tampon.
- Solution de dialyse selon l'une quelconque des revendications précédentes, dans laquelle le concentré acide est sélectionné à partir du groupe constitué par l'acide lactique/lactate, l'acide pyruvique/pyruvate, l'acide acétique/acétate, l'acide citrique/citrate, un produit intermédiaire du cycle de Krebs, l'acide chlorhydrique, et des mélanges de ceux-ci.
- Solution de dialyse selon l'une quelconque des revendications précédentes, dans laquelle les premier, deuxième et troisième composants sont contenus dans des première, deuxième et troisième chambres d'un conteneur à plusieurs chambres et dans laquelle les premier, deuxième et troisième composants peuvent être mélangés à l'intérieur du conteneur à plusieurs chambres.
- Solution de dialyse selon l'une quelconque des revendications précédentes, dans laquelle le polymère de glucose est de l'icodextrine.
- Solution de dialyse selon l'une quelconque des revendications précédentes, dans laquelle le pH du deuxième composant et le pH du troisième composant permettent d'obtenir, lorsque le premier composant, le deuxième composant et le troisième composant sont mélangés ensemble, une solution mélangée présentant un pH physiologiquement compatible qui est compris entre 6,5 et 7,6.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/866,206 US20050276868A1 (en) | 2004-06-10 | 2004-06-10 | Bicarbonate-based peritoneal dialysis solutions |
PCT/US2005/017995 WO2006001962A1 (fr) | 2004-06-10 | 2005-05-18 | Solutions a base de bicarbonate pour dialyse peritoneale |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1753437A1 EP1753437A1 (fr) | 2007-02-21 |
EP1753437B1 true EP1753437B1 (fr) | 2013-12-25 |
Family
ID=34971152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05754137.7A Active EP1753437B1 (fr) | 2004-06-10 | 2005-05-18 | Solutions a base de bicarbonate pour dialyse peritoneale |
Country Status (7)
Country | Link |
---|---|
US (2) | US20050276868A1 (fr) |
EP (1) | EP1753437B1 (fr) |
JP (1) | JP5690040B2 (fr) |
AR (1) | AR049298A1 (fr) |
MX (1) | MXPA06014254A (fr) |
TW (1) | TW200602065A (fr) |
WO (1) | WO2006001962A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070293441A1 (en) * | 2003-09-22 | 2007-12-20 | Baxter International Inc. | High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products |
US20050276868A1 (en) * | 2004-06-10 | 2005-12-15 | Bart Degreve | Bicarbonate-based peritoneal dialysis solutions |
US8202248B2 (en) | 2004-08-18 | 2012-06-19 | Sequana Medical Ag | Dialysis implant and methods of use |
US7544301B2 (en) | 2004-08-19 | 2009-06-09 | Hhd Llc | Citrate-based dialysate chemical formulations |
US8911390B2 (en) | 2009-03-31 | 2014-12-16 | Gambro Lundia Ab | Multipart fluid system and a system for regional citrate anticoagulation in an extracorporeal blood circuit |
BR112012001320B1 (pt) * | 2009-07-24 | 2021-10-05 | Crearene Ag | Solução de diálise, kit configurado para preparação de uma solução de diálise e preparação sólida |
DE102010039489A1 (de) * | 2010-08-18 | 2012-02-23 | Fresenius Medical Care Deutschland Gmbh | Konzentrat |
US9585810B2 (en) | 2010-10-14 | 2017-03-07 | Fresenius Medical Care Holdings, Inc. | Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser |
US20120199205A1 (en) | 2011-02-03 | 2012-08-09 | Fresenius Medical Care Deutschland Gmbh | System for preparing a medical fluid and method for preparing a medical fluid |
MY171156A (en) | 2011-06-24 | 2019-09-27 | Richard W C Lo | Multi-container systems and uses thereof |
US8585635B2 (en) | 2012-02-15 | 2013-11-19 | Sequana Medical Ag | Systems and methods for treating chronic liver failure based on peritoneal dialysis |
WO2016063811A1 (fr) * | 2014-10-23 | 2016-04-28 | ニプロ株式会社 | Corps rempli d'agent de dialyse |
WO2016156502A1 (fr) * | 2015-03-31 | 2016-10-06 | Gambro Lundia Ab | Emballage pour un concentré de liquide de dialyse acide contenant du citrate et du glucose |
ES2963823T3 (es) | 2016-05-06 | 2024-04-02 | Gambro Lundia Ab | Sistema para dosificar líquidos |
US20190151265A1 (en) * | 2016-05-06 | 2019-05-23 | Gambro Lundia Ab | Dialysis concentrate |
US10769244B2 (en) | 2016-08-26 | 2020-09-08 | Sequana Medical Nv | Systems and methods for managing and analyzing data generated by an implantable device |
US20190192556A1 (en) * | 2016-08-30 | 2019-06-27 | Nipro Corporation | Standard reagent kit for analysis of dialysis fluid, and aqueous solutions for standard reagent, dialysis fluid and substitution fluid for artificial kidney |
JP6642339B2 (ja) * | 2016-08-30 | 2020-02-05 | ニプロ株式会社 | 透析液分析用標準試薬キット |
JP7003493B2 (ja) * | 2017-08-28 | 2022-02-04 | ニプロ株式会社 | 透析液分析用標準試薬キット |
AU2017406365A1 (en) * | 2017-03-28 | 2019-10-03 | Hepa Wash Gmbh | Compositions and methods for regenerating carrier protein-containing multiple pass albumin dialysis fluid |
KR20200004341A (ko) * | 2017-05-05 | 2020-01-13 | 프레제니우스 메디칼 케어 도이칠란드 게엠베하 | 복막 투석 농축물, 복막 투석 백 및 지속 외래 복막 투석용 또는 자동 복막 투석용 세트 |
US11559618B2 (en) | 2017-05-24 | 2023-01-24 | Sequana Medical Nv | Formulations and methods for direct sodium removal in patients having severe renal dysfunction |
EP3703758A1 (fr) * | 2017-11-03 | 2020-09-09 | Gambro Lundia AB | Méthode et système permettant de fournir des fluides de dialyse péritonéale à concentrations de potassium variables |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993751A (en) * | 1972-11-27 | 1976-11-23 | Cybersol, Inc. | Process for stabilizing therapeutic compositions and article |
US3878664A (en) * | 1972-11-27 | 1975-04-22 | Cybersol | Process for producing a therapeutic composition |
CA1017249A (en) * | 1973-12-19 | 1977-09-13 | Chemo Drug Company | Injectable electrolyte solutions |
US3974034A (en) * | 1975-09-12 | 1976-08-10 | Cpc International Inc. | Malto-dextrins of improved stability prepared by enzymatic hydrolysis of oxidized starch |
US4182756A (en) * | 1977-11-21 | 1980-01-08 | Abbott Laboratories | High calorie solutions of low molecular weight glucose polymer mixtures useful for intravenous administration |
US4326955A (en) * | 1979-06-14 | 1982-04-27 | Diachem, Inc. | Hemodialysis with sodium bicarbonate dialysate prepared in plural stages |
US4756838A (en) * | 1980-02-21 | 1988-07-12 | Veltman Preston Leonard | Preparation of dry dialysate products |
US4489535A (en) * | 1980-10-02 | 1984-12-25 | Veltman Preston Leonard | Materials and method for preparing dialysis solutions containing bicarbonate ions |
US4339433A (en) * | 1981-01-09 | 1982-07-13 | Baxter Travenol Laboratories, Inc. | Additives for peritoneal dialysis solutions |
US4465488A (en) * | 1981-03-23 | 1984-08-14 | Baxter Travenol Laboratories, Inc. | Collapsible multi-chamber medical fluid container |
US4761237A (en) * | 1981-07-10 | 1988-08-02 | Baxter Travenol Laboratories, Inc. | Peritoneal dialysis solution containing carbohydrate polymers |
US4879280A (en) * | 1981-09-24 | 1989-11-07 | Fresenius Ag | Dialysis solution for use in intraperitoneal dialysis |
US4396383A (en) * | 1981-11-09 | 1983-08-02 | Baxter Travenol Laboratories, Inc. | Multiple chamber solution container including positive test for homogenous mixture |
US4436232A (en) * | 1981-11-16 | 1984-03-13 | Kbl Corporation | Bracket for motorcycle lock |
US4536469A (en) * | 1981-11-23 | 1985-08-20 | Raytheon Company | Semiconductor structures and manufacturing methods |
US6077836A (en) * | 1983-01-12 | 2000-06-20 | Ml Laboratotries, Plc | Peritoneal dialysis and compositions for use therein |
US4886789A (en) * | 1983-01-12 | 1989-12-12 | M. L. Laboratories Plc | Peritoneal dialysis and compositions for use therein |
US4604379A (en) * | 1984-06-18 | 1986-08-05 | Curators Of The University Of Missouri | Dialysis solutions containing cross-linked gelatin |
US4663166A (en) * | 1984-06-22 | 1987-05-05 | Veech Richard L | Electrolyte solutions and in vivo use thereof |
US4668400A (en) * | 1984-06-22 | 1987-05-26 | Veech Richard L | Hemodialysis processes and hemodialysis solutions |
US6020007A (en) * | 1984-06-22 | 2000-02-01 | Btg International Limited | Fluid therapy with l-lactate and/or pyruvate anions |
US5100677A (en) * | 1985-12-18 | 1992-03-31 | Veech Richard L | Fluid therapy with various organic anions |
JPS61247466A (ja) * | 1985-04-25 | 1986-11-04 | テルモ株式会社 | 腹膜透析用透析液 |
US6248726B1 (en) * | 1985-06-22 | 2001-06-19 | M L Laboratories Plc | Method of peritoneal dialysis using glucose polymer solutions |
US5091094A (en) * | 1985-06-24 | 1992-02-25 | Veech Richard L | Hemodialysis processes & hemodialysis solutions |
GB8521712D0 (en) * | 1985-08-31 | 1985-10-02 | Giltech Ltd | Solution for peritoneal dialysis |
EP0218900B1 (fr) * | 1985-09-10 | 1992-01-22 | Research Corporation Technologies, Inc. | Agents osmotiques pour dialyse péritonéale |
US4976683A (en) * | 1986-06-20 | 1990-12-11 | Abbott Laboratories | Peritoneal dialysis method |
GR870129B (en) * | 1987-01-27 | 1987-02-04 | Giatzidis Ippokratis | Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis |
DE3812525C1 (fr) * | 1988-04-15 | 1989-06-22 | Fresenius Ag, 6380 Bad Homburg, De | |
US5092838A (en) * | 1989-11-30 | 1992-03-03 | Baxter International Inc. | Histidine buffered peritoneal dialysis solution |
AU627309B2 (en) * | 1989-05-26 | 1992-08-20 | Terumo Kabushiki Kaisha | Preparation for blood dialysis and method for production thereof |
DE3917251A1 (de) * | 1989-05-26 | 1990-11-29 | Fresenius Ag | Natriumbicarbonat enthaltendes konzentrat sowie verfahren zur herstellung einer dialysierfluessigkeit |
US5071558A (en) * | 1989-08-11 | 1991-12-10 | Nikkiso Co., Ltd. | Sodium bicarbonate dialysate |
US5161248A (en) * | 1989-10-02 | 1992-11-03 | Motorola, Inc. | Method of predicting cell-to-cell hand-offs for a satellite cellular communications system |
SE505967C2 (sv) * | 1990-10-15 | 1997-10-27 | Gambro Ab | Förfarande respektive anläggning för beredning av en medicinsk lösning, t ex en dialyslösning |
DE4125819A1 (de) * | 1991-08-03 | 1993-02-04 | Rolf Prof Dr Med Zander | Waessrige loesung und deren verwendung |
US5827820A (en) * | 1992-04-06 | 1998-10-27 | Baxter International Inc. | Aqueous peritoneal dialysis solution |
DE4242926C2 (de) * | 1992-12-18 | 1994-12-15 | Fresenius Ag | Dialyselösung für die Peritonealdialyse |
DK0636018T3 (da) * | 1993-01-19 | 1997-12-08 | Baxter Int | Flerkammerbeholder |
US6306836B1 (en) * | 1994-01-21 | 2001-10-23 | Baxter International Inc. | Peritoneal dialysis solutions containing maltodextrins and amino acids |
GB9411009D0 (en) * | 1994-06-02 | 1994-07-20 | Giltech Ltd | Dialysis fluid |
SE510030C2 (sv) * | 1995-08-08 | 1999-04-12 | Gambro Ab | Förfarande för blandning av steril medicinsk lösning samt behållare för utförande av förfarandet |
SE507052C2 (sv) * | 1995-08-08 | 1998-03-23 | Gambro Ab | Behållare avsedd att innehålla steril medicinsk lösning |
CA2155910C (fr) * | 1995-08-11 | 1999-12-14 | George Wu | Solution aqueuse biocompatible pour utilisation en dialyse peritoneale ambulatoire continue |
JP3623294B2 (ja) * | 1995-11-28 | 2005-02-23 | 株式会社新素材総合研究所 | 電解質液が収容された医療用容器及びその製造方法 |
SE9600631D0 (sv) * | 1996-02-20 | 1996-02-20 | Gambro Ab | Use of a solution comprising glucose for peritonial dialysis having reduced formation of AGE products |
AR006049A1 (es) * | 1996-03-01 | 1999-07-21 | Johnson & Johnson Consumer | Una emulsion de aceite en agua |
DE19631124A1 (de) * | 1996-08-01 | 1998-02-05 | Fresenius Medical Care De Gmbh | Verfahren zur Herstellung einer Bicarbonat enthaltenden Infusions- oder Dialysierlösung |
GB9714218D0 (en) * | 1997-07-04 | 1997-09-10 | Allied Therapeutics Ltd | Peritoneal dialysis fluid |
WO1999009953A1 (fr) * | 1997-08-22 | 1999-03-04 | Shimizu Pharmaceutical Co., Ltd. | Preparation contenant du glucose |
SE510587C2 (sv) * | 1997-10-07 | 1999-06-07 | Gambro Lundia Ab | Koncentrat för dialyslösning och användning därav |
DE19748290B8 (de) * | 1997-10-31 | 2009-09-03 | Fresenius Medical Care Deutschland Gmbh | Lösung für die Peritonealdialyse |
EP0958832B1 (fr) * | 1998-05-21 | 2006-01-25 | Nipro Corporation | Solution pour dialyse péritonéale contenant de l'albumine |
EP0980685B1 (fr) * | 1998-06-17 | 2006-01-25 | Nipro Corporation | Utilisation d'un liquide pour la fabrication d'un liquide de dialyse pour la dialyse péritonéale continue avec recirculation |
SE521219C2 (sv) * | 1998-10-23 | 2003-10-14 | Gambro Ab | Metod och anordning för att reducera nedbrytning av värmekänsliga komponenter i medicinska substanser under värmesterilisering |
US6770148B1 (en) * | 1998-12-04 | 2004-08-03 | Baxter International Inc. | Peritoneal dialysis solution containing modified icodextrins |
DE69815113T2 (de) * | 1998-12-04 | 2004-04-08 | Lucent Technologies Inc. | Fehlerverschleierung und -korrektur für Sprach-, Bild- und Videosignale |
DE19912850B4 (de) * | 1999-03-22 | 2005-04-07 | Fresenius Medical Care Deutschland Gmbh | Lösung, insbesondere für Hämo- oder Peritonealdialyse, sowie Verfahren zu deren Herstellung |
EP1165148A1 (fr) * | 1999-03-30 | 2002-01-02 | Gambro Lundia AB | Procede et appareil de sterilisation d'un fluide sensible a la chaleur |
US8105258B2 (en) * | 1999-04-26 | 2012-01-31 | Baxter International Inc. | Citrate anticoagulation system for extracorporeal blood treatments |
US6251437B1 (en) * | 1999-07-13 | 2001-06-26 | Minntech Corporation | Liquid/powder acid concentrate for dialysate and a method of making the same |
US6309673B1 (en) * | 1999-09-10 | 2001-10-30 | Baxter International Inc. | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy |
US20030202958A1 (en) * | 1999-10-15 | 2003-10-30 | Strickland Alan D. | Dialysis solution including polyglycol osmotic agent |
DE19955578C1 (de) * | 1999-11-18 | 2001-09-06 | Fresenius Medical Care De Gmbh | Mehrkammerbehälter, mit Glucosekonzentratkompartiment und Salzsäurekonzentratkompartiment |
SE0001939D0 (sv) * | 2000-05-25 | 2000-05-25 | Gambro Lundia Ab | Medical solution and use thereof |
US6582734B1 (en) * | 2000-07-20 | 2003-06-24 | Ecolab Inc. | Antimicrobial composition useful for the treatment of bovine mastitis |
WO2002049694A2 (fr) * | 2000-12-20 | 2002-06-27 | Dialysis Solutions Inc. | Solutions concentrees steriles de dialyse exemptes de bicarbonate |
US6787039B2 (en) * | 2001-01-26 | 2004-09-07 | Degussa Ag | Amino acid composition for hemodialysis |
EP1377594A4 (fr) * | 2001-04-10 | 2004-06-30 | Danisco Usa Inc | Polymerisation de mono et de disaccharides avec des acides monocarboxyliques et des lactones |
ITMI20020516A1 (it) * | 2002-03-12 | 2003-09-12 | Gambro Lundia Ab | Liquidi per dialisi peritoneale emodialisi e reintegrazione |
DE10217356B4 (de) * | 2002-04-18 | 2012-03-29 | Fresenius Medical Care Deutschland Gmbh | Lösung für die Peritonealdialyse |
US20040121982A1 (en) * | 2002-12-20 | 2004-06-24 | Leo Martis | Biocompatible dialysis fluids containing icodextrins |
US7053059B2 (en) * | 2003-07-25 | 2006-05-30 | Baxter International Inc. | Dialysis solutions with reduced levels of glucose degradation products |
US20050276868A1 (en) * | 2004-06-10 | 2005-12-15 | Bart Degreve | Bicarbonate-based peritoneal dialysis solutions |
-
2004
- 2004-06-10 US US10/866,206 patent/US20050276868A1/en not_active Abandoned
-
2005
- 2005-05-18 WO PCT/US2005/017995 patent/WO2006001962A1/fr not_active Application Discontinuation
- 2005-05-18 EP EP05754137.7A patent/EP1753437B1/fr active Active
- 2005-05-18 MX MXPA06014254A patent/MXPA06014254A/es not_active Application Discontinuation
- 2005-05-18 JP JP2007527538A patent/JP5690040B2/ja active Active
- 2005-05-24 TW TW094116875A patent/TW200602065A/zh unknown
- 2005-06-09 AR ARP050102368A patent/AR049298A1/es not_active Application Discontinuation
-
2006
- 2006-06-22 US US11/425,911 patent/US20060226080A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1753437A1 (fr) | 2007-02-21 |
AR049298A1 (es) | 2006-07-12 |
JP5690040B2 (ja) | 2015-03-25 |
JP2008502722A (ja) | 2008-01-31 |
US20060226080A1 (en) | 2006-10-12 |
TW200602065A (en) | 2006-01-16 |
US20050276868A1 (en) | 2005-12-15 |
MXPA06014254A (es) | 2007-03-12 |
WO2006001962A1 (fr) | 2006-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1753437B1 (fr) | Solutions a base de bicarbonate pour dialyse peritoneale | |
US7053059B2 (en) | Dialysis solutions with reduced levels of glucose degradation products | |
EP1585531B1 (fr) | Liquides de dialyse biocompatibles contenant des icodextrines | |
EP2322236B9 (fr) | Solutions à base de bicarbonate pour thérapies de dialyse | |
KR101548027B1 (ko) | 피로포스페이트를 함유하는 멸균된 투석 용액 | |
EP1511501A1 (fr) | Solution stable a base de bicarbonate contenue dans un recipient unique | |
JP4061775B2 (ja) | アルブミン含有腹膜透析液 | |
JP2009522054A (ja) | ヘパリンを含む滅菌済腹膜透析溶液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20061201 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
17Q | First examination report despatched |
Effective date: 20070322 |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAXTER HEALTHCARE S.A. Owner name: BAXTER INTERNATIONAL INC. |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602005042252 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0033100000 Ipc: A61M0001280000 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/50 20060101ALI20130502BHEP Ipc: A61M 1/28 20060101AFI20130502BHEP Ipc: A61K 33/00 20060101ALI20130502BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20130730 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 646225 Country of ref document: AT Kind code of ref document: T Effective date: 20140115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602005042252 Country of ref document: DE Effective date: 20140213 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20131225 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 646225 Country of ref document: AT Kind code of ref document: T Effective date: 20131225 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140425 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140428 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602005042252 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20140926 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140518 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602005042252 Country of ref document: DE Effective date: 20140926 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140531 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140531 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140518 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140326 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131225 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20050518 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230405 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240419 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240418 Year of fee payment: 20 |